|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:antidote
|
andexanet alfa (for reversal)
|
|
gptkbp:approvalYear
|
2008
2011
|
|
gptkbp:approvedBy
|
gptkb:Germany
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100% (10 mg dose)
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:chemicalFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:eliminatedIn
|
renal and fecal
|
|
gptkbp:genericName
|
gptkb:rivaroxaban
|
|
gptkbp:halfLife
|
5-9 hours (young), 11-13 hours (elderly)
|
|
gptkbp:hasBoxedWarning
|
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xarelto
|
|
gptkbp:indication
|
prevention of venous thromboembolism after hip or knee replacement surgery
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bayer
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketedAs
|
gptkb:Bayer
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
factor Xa inhibitor
|
|
gptkbp:patentExpired
|
2024 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionForm
|
gptkb:tablet
oral suspension
|
|
gptkbp:riskFactor
|
increased risk of bleeding with other anticoagulants
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:bfsParent
|
gptkb:Bayer
|
|
gptkbp:bfsLayer
|
5
|